GENFIT: Funding, Investors & Team (Sep 2026)
GENFIT is a biopharmaceutical company focused on finding new treatments for metabolic and liver diseases with unmet medical needs. Their research is based on a strong foundation of in-house knowledge and a commitment to excellence. They use specific nuclear receptors as targets for drug discovery and have expertise in scientific, clinical, and bioinformatics capabilities. Co-founder Professor Bart Staels, a world-renowned expert in nuclear receptors, leads their Scientific Advisory Board to provide essential knowledge and support in their role as a leader in metabolic solutions.
GENFIT has raised $29.8M across 1 funding round on record, the most recent an undisclosed round of $29.8M announced in May 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
GENFIT Company Profile and Key Stats
Latest funding round on record: May 2025.
GENFIT Funding Rounds
GENFIT Founders and Leadership Team
No contact details are on record for this team yet.
GENFIT Funding Compared to Other Biotechnology Startups
GENFIT's latest round of $29.8M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like GENFIT in Biotechnology and Loos
Companies Similar to GENFIT
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
GENFIT Funding FAQs
What does GENFIT do?
GENFIT is a biopharmaceutical company focused on finding new treatments for metabolic and liver diseases with unmet medical needs. Their research is based on a strong foundation of in-house knowledge and a commitment to excellence. They use specific nuclear receptors as targets for drug discovery and have expertise in scientific, clinical, and bioinformatics capabilities. Co-founder Professor Bart Staels, a world-renowned expert in nuclear receptors, leads their Scientific Advisory Board to provide essential knowledge and support in their role as a leader in metabolic solutions.
How much funding has GENFIT raised?
GENFIT has raised $29.8M across 1 round on record. The most recent is an undisclosed round of $29.8M announced in May 2025.
When did GENFIT last raise funding?
GENFIT's most recent funding round on record is an undisclosed round of $29.8M, announced in May 2025.
Who founded GENFIT?
FundedIQ lists Bart Staels (Founder) at GENFIT.
Where is GENFIT headquartered?
GENFIT is based in Loos, Nord-Pas-De-Calais, France.
How many employees does GENFIT have?
GENFIT is in the 101-250 employee band.
How does GENFIT's funding compare to other Biotechnology startups?
GENFIT's latest round of $29.8M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's GENFIT Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for GENFIT is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.